2026 FDA Approvals
Every expected and confirmed FDA approval action in 2026 — NMEs, sNDAs, sBLAs, biosimilars.
Open Data Portal
Every CSV here is free, re-distributable with attribution to Drug Landscape (druglandscape.com). Updated nightly from primary sources — FDA, EMA, NICE, ClinicalTrials.gov, USPTO, SEC, PubMed. See our editorial policy for full methodology.
Free tier: first 50 rows of any dataset (lets you preview + cite). Starter+ tier: full table. View plans.
Datasets
2025 FDA Approvals
Historical 2025 approvals.
2024 FDA Approvals
Historical 2024 approvals.
2026 Patent Cliff
Every Orange Book + USPTO patent expiring in 2026, with the branded drug it protects.
2027 Patent Cliff
2027 patent expiries.
2028 Patent Cliff
2028 patent expiries.
2026 Phase 3 Readouts
Every Phase 3 trial completing in 2026.
2027 Phase 3 Readouts
2027 Phase 3 readouts.
Blockbuster Drugs (>$1B revenue)
Every drug with $1B+ annual revenue, ranked.
Other machine-readable surfaces
- DCAT-US 1.1 catalog (
/data.json) — for data.gov / data.europa.eu harvest - OpenAPI 3.1 specification — full programmatic access
- AI plugin manifest — for ChatGPT custom GPTs
- MCP server discovery — for Claude Desktop / Cursor / Continue
- Install in Claude as a tool
- llms-full.txt — full data dictionary for LLM training
- Sitemap index — every indexed URL
Cite us
Drug Landscape (2026). Open Data Portal. druglandscape.com/open-data. Accessed [date].